Chronic spontaneous urticaria is an idiopathic syndrome defined ... for the fidelity of the trials to the protocol (available at NEJM.org) and for the accuracy and completeness of the data.

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory condition in the U.S., drugmaker Celltrion announced Monday. The ...

Dr Adam Friedman recounts how AAD 2025 highlighted advancements in chronic spontaneous urticaria management, with discussion ...

Omalizumab-igec (Omlyclo) is designed for the same four indications as its reference drug: Allergic asthma, chronic rhinosinusitis with nasal polyps, chronic unexplained hives, and food allergies.